Congress Asset Management Co. MA Has $41.77 Million Stake in Integer Holdings Co. (NYSE:ITGR)

Congress Asset Management Co. MA lifted its position in Integer Holdings Co. (NYSE:ITGR) by 12.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 421,524 shares of the medical equipment provider’s stock after purchasing an additional 46,776 shares during the quarter. Congress Asset Management Co. MA owned 1.26% of Integer worth $41,765,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Swiss National Bank grew its position in Integer by 1.0% in the third quarter. Swiss National Bank now owns 73,200 shares of the medical equipment provider’s stock valued at $5,741,000 after acquiring an additional 700 shares during the period. Janney Montgomery Scott LLC grew its position in Integer by 1.5% in the third quarter. Janney Montgomery Scott LLC now owns 9,507 shares of the medical equipment provider’s stock valued at $746,000 after acquiring an additional 142 shares during the period. Charles Schwab Investment Management Inc. grew its position in Integer by 1.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 379,432 shares of the medical equipment provider’s stock valued at $29,759,000 after acquiring an additional 4,640 shares during the period. Van ECK Associates Corp grew its holdings in shares of Integer by 22.0% during the third quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 313 shares during the last quarter. Finally, Pathstone Family Office LLC bought a new stake in shares of Integer during the third quarter worth $233,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ITGR has been the topic of several research analyst reports. Citigroup increased their target price on Integer from $118.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, May 22nd. Benchmark restated a “buy” rating and set a $130.00 target price on shares of Integer in a report on Friday, May 10th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and upped their price target for the company from $105.00 to $135.00 in a research note on Monday, April 15th. Truist Financial assumed coverage on Integer in a research note on Wednesday, May 15th. They set a “buy” rating and a $137.00 price target on the stock. Finally, CL King assumed coverage on Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $128.00.

Integer Stock Down 0.4 %

Shares of NYSE ITGR traded down $0.42 during mid-day trading on Friday, reaching $116.31. 342,511 shares of the company’s stock were exchanged, compared to its average volume of 239,117. The firm has a market capitalization of $3.90 billion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.72 and a beta of 1.16. The company has a current ratio of 3.32, a quick ratio of 2.01 and a debt-to-equity ratio of 0.76. The business has a fifty day simple moving average of $117.28 and a 200 day simple moving average of $108.65. Integer Holdings Co. has a twelve month low of $69.40 and a twelve month high of $123.99.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The company had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. Integer’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. As a group, equities analysts expect that Integer Holdings Co. will post 5.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Integer news, VP Tommy P. Thomas sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $114.00, for a total value of $171,000.00. Following the completion of the transaction, the vice president now directly owns 2,813 shares in the company, valued at $320,682. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP John A. Harris sold 312 shares of Integer stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $113.00, for a total transaction of $35,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,157 shares in the company, valued at approximately $130,741. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Tommy P. Thomas sold 1,500 shares of Integer stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $114.00, for a total value of $171,000.00. Following the transaction, the vice president now owns 2,813 shares of the company’s stock, valued at $320,682. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,936 shares of company stock worth $2,130,937. 2.00% of the stock is owned by corporate insiders.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.